Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Daratumumab	TA510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	Hospital use only
Darbepoetin alfa (Aranesp)	TA323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	NHSE commissioned renal dialysis. CCG commissioned for use in cancer - NICE TA323.
Daridorexant (QUVIVIQ®)		TA922: Daridorexant for treating long-term insomnia
Dasatinib tablets	TA425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia TA426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia	Hospital use only
Deep Blue®		Lifting agent for use during complex EMR/ESD procedures
Deferiprone tablets (Ferriprox)		NHSE commissioned.
Degarelix injection	TA404 - Degarelix for treating advanced hormone-dependent prostate cancer	Supported by ESCA
Demeclocycline capsules		For the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone. Unlicensed.
Denosumab injection (Prolia®)	TA204 - Denosumab for the prevention of osteoporotic fractures in postmenopausal women	ESCA
Dermatonics Once Heel Balm®		Specialist recommendation for epidermolysis bullosa and diabetes patients only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.